News

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...
John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal ...
A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...
In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...
An expert discusses the multifaceted nature of CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emphasizing the need for early multidisciplinary coordination to address ...
Katherine McDaniel, MD, discusses fertility preservation options for patients facing a cancer diagnosis and how the landscape has changed over the past two decades.
Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.
FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and ...
A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...
Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into ...
During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...